scispace - formally typeset
C

Christopher L. Plaisier

Researcher at Arizona State University

Publications -  56
Citations -  5827

Christopher L. Plaisier is an academic researcher from Arizona State University. The author has contributed to research in topics: Gene & Biology. The author has an hindex of 23, co-authored 46 publications receiving 3840 citations. Previous affiliations of Christopher L. Plaisier include University of California, Los Angeles & University of Utah.

Papers
More filters
Journal ArticleDOI

The Immune Landscape of Cancer

TL;DR: An extensive immunogenomic analysis of more than 10,000 tumors comprising 33 diverse cancer types by utilizing data compiled by TCGA identifies six immune subtypes that encompass multiple cancer types and are hypothesized to define immune response patterns impacting prognosis.
Journal ArticleDOI

Integrating Genetic and Network Analysis to Characterize Genes Related to Mouse Weight

TL;DR: This work uses microarray and genetic marker data from an F2 mouse intercross to examine the large-scale organization of the gene co-expression network in liver, and annotates several gene modules in terms of 22 physiological traits.
Journal ArticleDOI

Targeted mutagenesis using zinc-finger nucleases in Arabidopsis

TL;DR: Data indicate that ZFNs can form the basis of a highly efficient method for targeted mutagenesis of plant genes and demonstrate efficient transmission of the ZFN-induced mutations.
Journal ArticleDOI

A systems genetics approach implicates USF1, FADS3, and other causal candidate genes for familial combined hyperlipidemia.

TL;DR: It is hypothesized that a common SNP in the 3' untranslated region of the upstream transcription factor 1 (USF1), rs3737787, may affect lipid traits by influencing gene expression levels, and this possibility utilizing the Mexican population, which has a high predisposition to dyslipidemia.
Journal ArticleDOI

A miRNA-regulatory network explains how dysregulated miRNAs perturb oncogenic processes across diverse cancers

TL;DR: The utility of FIRM is demonstrated by inferring a cancer-miRNA regulatory network through the analysis of 2240 gene coexpression signatures from 46 cancers and a subset of 13 miRNAs that regulate oncogenic processes across diverse cancers are discovered.